ScoreWhy is Beryl Drugs Ltd ?
1
Weak Long Term Fundamental Strength with an average Return on Capital Employed (ROCE) of 8.19%
- Poor long term growth as Net Sales has grown by an annual rate of 6.22% and Operating profit at 9.30% over the last 5 years
- Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of 0.94
2
Positive results in Mar 26
- PBDIT(Q) Highest at Rs 1.34 cr.
- PBT LESS OI(Q) Highest at Rs 0.87 cr.
- PAT(Q) Highest at Rs 0.56 cr.
3
With ROCE of 7.6, it has a Very Attractive valuation with a 1.2 Enterprise value to Capital Employed
- The stock is trading at a discount compared to its peers' average historical valuations
- Over the past year, while the stock has generated a return of 24.39%, its profits have fallen by -16%
4
Majority shareholders : Non Institution
5
Market Beating performance in long term as well as near term
- Along with generating 24.39% returns in the last 1 year, the stock has outperformed BSE500 in the last 3 years, 1 year and 3 months
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to Beryl Drugs should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Beryl Drugs for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
Beryl Drugs
24.39%
0.36
67.78%
Sensex
-1.65%
-0.12
13.58%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
6.22%
EBIT Growth (5y)
9.30%
EBIT to Interest (avg)
0.94
Debt to EBITDA (avg)
2.51
Net Debt to Equity (avg)
0.22
Sales to Capital Employed (avg)
1.58
Tax Ratio
27.12%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
6.35%
ROE (avg)
5.66%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
29
Industry P/E
37
Price to Book Value
1.25
EV to EBIT
14.49
EV to EBITDA
6.01
EV to Capital Employed
1.20
EV to Sales
0.75
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
7.63%
ROE (Latest)
4.25%
Loading Valuation Snapshot...
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Mildly Bullish
Dow Theory
No Trend
Mildly Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend7What is working for the Company
PBDIT(Q)
Highest at Rs 1.34 cr.
PBT LESS OI(Q)
Highest at Rs 0.87 cr.
PAT(Q)
Highest at Rs 0.56 cr.
EPS(Q)
Highest at Rs 1.10
0What is not working for the Company
NO KEY NEGATIVE TRIGGERS
Loading Valuation Snapshot...
Here's what is working for Beryl Drugs
Operating Profit (PBDIT) - Quarterly
Highest at Rs 1.34 cr.
in the last five quartersMOJO Watch
Near term Operating Profit trend is positive
Operating Profit (Rs Cr)
Profit Before Tax less Other Income (PBT) - Quarterly
Highest at Rs 0.87 cr.
in the last five quartersMOJO Watch
Near term PBT trend is positive
PBT less Other Income (Rs Cr)
Profit After Tax (PAT) - Quarterly
Highest at Rs 0.56 cr.
in the last five quartersMOJO Watch
Near term PAT trend is positive
PAT (Rs Cr)
Earnings per Share (EPS) - Quarterly
Highest at Rs 1.10
in the last five quartersMOJO Watch
Increasing profitability; company has created higher earnings for shareholders
EPS (Rs)
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
